noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

U.S. Fish and Wildlife Service

Weekly DatCall Report
California Department of[...]

Eastbound I 8 Connector to SR 67 Closed Thursday, 5/16
NRDC - Natural Resources Defense[...]

Legislators, Advocates Urge Albany to Take Action to Protect Against[...]

Healthcare

Results

Luye Pharma Group Ltd.

03/04/2024 | Press release | Distributed by Public on 03/04/2024 22:46

First Patient Enrolled for Phase 3 Clinical Study of Luye Pharma’s Irinotecan Hydrochloride Liposome Injection (LY01610)

Read this content

Click here to read the original version at the source's official website. The text of this article is not available at the moment.

Sharing and Personal Tools

Please select the service you want to use:

Smartlinks | Luye Pharma Group Ltd. | News | Health | Science | Research | Company News | Top Company News | Business Announcement | Products and Services | Pharmaceuticals | Securities Issuers | Pharmaceutical Companies | Frankfurt Stock Exchange | Hong Kong Stock Exchange (HKEX) | Berlin Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | OTC Markets

Back